Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis

Jun Yu, Radu Daniel Rudic, William C. Sessa

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Endothelial dysfunction, defined as a deficit in the bioavailability of nitric oxide (NO), occurs as sequelae of many vascular diseases; however, the utility of supplementing NO to obviate the extent of disease is understudied. Here, we examined if prolonged treatment with an NO-releasing form of aspirin (NO-ASA) can influence neointimal remodeling of femoral arteries of hypercholesterolemic ApoE (-/-) mice. Treatment of ApoE (-/-) mice with NO-ASA, but not aspirin (ASA), improved neointimal remodeling post-injury. NO-ASA treatment increased lumen diameters and reduced intimal-to -medial ratios of injured femoral arteries compared with ASA- or vehicle-treated mice. The reduction in lumen diameter in NO-ASA-treated mice was associated with a marked reduction in CD45-positive inflammatory cells and an increased number of TUNEL-positive cells. Thus, NO-ASA, by virtue of releasing NO, can reduce vascular inflammation and promote apoptosis during vascular remodeling associated with neointimal thickening.

Original languageEnglish (US)
Pages (from-to)825-832
Number of pages8
JournalLaboratory Investigation
Volume82
Issue number7
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Vascular System Injuries
Nitric Oxide
Apoptosis
Inflammation
Apolipoproteins E
Femoral Artery
Tunica Intima
In Situ Nick-End Labeling
nitroaspirin
Vascular Diseases
Biological Availability
Aspirin
Blood Vessels
Cell Count
Wounds and Injuries

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. / Yu, Jun; Rudic, Radu Daniel; Sessa, William C.

In: Laboratory Investigation, Vol. 82, No. 7, 01.01.2002, p. 825-832.

Research output: Contribution to journalArticle

@article{1cbb703f0bdb48f99828b28b112439e4,
title = "Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis",
abstract = "Endothelial dysfunction, defined as a deficit in the bioavailability of nitric oxide (NO), occurs as sequelae of many vascular diseases; however, the utility of supplementing NO to obviate the extent of disease is understudied. Here, we examined if prolonged treatment with an NO-releasing form of aspirin (NO-ASA) can influence neointimal remodeling of femoral arteries of hypercholesterolemic ApoE (-/-) mice. Treatment of ApoE (-/-) mice with NO-ASA, but not aspirin (ASA), improved neointimal remodeling post-injury. NO-ASA treatment increased lumen diameters and reduced intimal-to -medial ratios of injured femoral arteries compared with ASA- or vehicle-treated mice. The reduction in lumen diameter in NO-ASA-treated mice was associated with a marked reduction in CD45-positive inflammatory cells and an increased number of TUNEL-positive cells. Thus, NO-ASA, by virtue of releasing NO, can reduce vascular inflammation and promote apoptosis during vascular remodeling associated with neointimal thickening.",
author = "Jun Yu and Rudic, {Radu Daniel} and Sessa, {William C.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1097/01.LAB.0000018828.61722.BD",
language = "English (US)",
volume = "82",
pages = "825--832",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis

AU - Yu, Jun

AU - Rudic, Radu Daniel

AU - Sessa, William C.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Endothelial dysfunction, defined as a deficit in the bioavailability of nitric oxide (NO), occurs as sequelae of many vascular diseases; however, the utility of supplementing NO to obviate the extent of disease is understudied. Here, we examined if prolonged treatment with an NO-releasing form of aspirin (NO-ASA) can influence neointimal remodeling of femoral arteries of hypercholesterolemic ApoE (-/-) mice. Treatment of ApoE (-/-) mice with NO-ASA, but not aspirin (ASA), improved neointimal remodeling post-injury. NO-ASA treatment increased lumen diameters and reduced intimal-to -medial ratios of injured femoral arteries compared with ASA- or vehicle-treated mice. The reduction in lumen diameter in NO-ASA-treated mice was associated with a marked reduction in CD45-positive inflammatory cells and an increased number of TUNEL-positive cells. Thus, NO-ASA, by virtue of releasing NO, can reduce vascular inflammation and promote apoptosis during vascular remodeling associated with neointimal thickening.

AB - Endothelial dysfunction, defined as a deficit in the bioavailability of nitric oxide (NO), occurs as sequelae of many vascular diseases; however, the utility of supplementing NO to obviate the extent of disease is understudied. Here, we examined if prolonged treatment with an NO-releasing form of aspirin (NO-ASA) can influence neointimal remodeling of femoral arteries of hypercholesterolemic ApoE (-/-) mice. Treatment of ApoE (-/-) mice with NO-ASA, but not aspirin (ASA), improved neointimal remodeling post-injury. NO-ASA treatment increased lumen diameters and reduced intimal-to -medial ratios of injured femoral arteries compared with ASA- or vehicle-treated mice. The reduction in lumen diameter in NO-ASA-treated mice was associated with a marked reduction in CD45-positive inflammatory cells and an increased number of TUNEL-positive cells. Thus, NO-ASA, by virtue of releasing NO, can reduce vascular inflammation and promote apoptosis during vascular remodeling associated with neointimal thickening.

UR - http://www.scopus.com/inward/record.url?scp=0036311339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036311339&partnerID=8YFLogxK

U2 - 10.1097/01.LAB.0000018828.61722.BD

DO - 10.1097/01.LAB.0000018828.61722.BD

M3 - Article

C2 - 12118084

AN - SCOPUS:0036311339

VL - 82

SP - 825

EP - 832

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 7

ER -